Pressure-enabled Retrograde Occlusive Therapy With Embolization for Control of Thyroid Disease (PROTECT Registry): A Multicenter Registry

Inclusion criteria

• Adults, 18 years and or older and 89 years or younger
• Having undergone PED-TAE using the TriNav Infusion System
• Meeting one of the following criteria:

• Documented subclinical and or clinical hyperthyroidism in the presence of a toxic multinodular goiter or a toxic nodule > 20 ml
• Patients' ineligible or refusing surgery, radio-iodine therapy or percutaneous ablation
• Non-functioning multinodular goiters or nodule causing compressive symptoms including but not limited to neck pain, dysphagia, stridor, exercise induced dyspnea and/or pressure symptoms
• Bethesda category 2-3 (benign, or atypia or follicular lesion of undetermined significance) on 2 separate fine-needle aspiration biopsy (FNAB) results with a benign molecular profile with patient declining surgical resection

Exclusion criteria

• Renal insufficiency
• Unable to tolerate angiography including pregnancy and severe allergy to contrast media
• Bethesda 4-6 on FNAB (suspicious for follicular neoplasm, suspicious for malignancy, or malignant)
• <18 years old or >89 years old
• Graves' disease or inflammatory thyroiditis (Hashimoto's) or other condition with the presence of an extensive collateral network as demonstrated or initial angiography
• Presence of a bovine arch or any other anatomical variant with no inferior thyroid artery present
• Prior thyroid thermal ablation